Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan;30(1):70–78. doi: 10.3201/eid3001.230414

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.

PMC Copyright notice

Cumulative hazards for all-cause mortality outcome events in study of effectiveness of vaccines and antiviral drugs in preventing severe and fatal COVID-19, Hong Kong. Cumulative hazards were compared among age groups, patients prescribed oral antiviral drugs, and those unvaccinated or vaccinated with CoronaVac or Comirnaty vaccines. A) No antiviral drugs, B) molnupiravir, C) nirmatrelvir/ritonavir. Antiviral drugs were prescribed within 5 days after confirmation of a COVID-19 diagnosis. Colors indicate age groups within each treatment group.